GBIO (Generation Bio Co.) Expected net earnings per share growth this year

Corporate emblem and logo of Generation Bio Co. (GBIO)

High R&D costs in the absence of revenue are already priced in, as confirmed by the annual earnings per share growth indicator. The value of 34.20 describes the current status of the metric against this trend. Generation Bio Co. (GBIO) is developing non-viral gene delivery systems via the RapidSNA platform, leveraging its own development centers for infinite DNA chains to treat genetic pathologies.

Earnings per share growth in current year: Generation Bio Co. (GBIO) for 07/04/2022 - 02/21/2026

Financial and market metric breakdowns for generationbio.com (GBIO)

- share price and expert price forecast:
Price Generation Bio|GBIO - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization GBIO|GBIO - Total Company Value
- shareholders' equity book value data:
Net Asset Value per Share Generation Bio|GBIO - Company Book Value|Capitalization to Book Value Ratio generationbio.com|GBIO - Cumulative Company Assets
- debt and liquidity details:
All Debt to Shareholders' Equity Ratio Generation Bio Co.|GBIO - Long-Term Debt to Capital|Short-Term Debt to Equity Generation Bio|GBIO - Company Aggregate Debts|Debts to Net Assets GBIO|GBIO - Company Long-Term Debt|Short-Term Debt Generation Bio|Intermediate Coverage Ratio generationbio.com
- company profitability and valuation multiples indicators:
GBIO - Net Profit|Future Profit Generation Bio Co.|GBIO - Price to Earnings Ratio|Projected Price to Earnings Ratio Generation Bio|GBIO - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio GBIO|GBIO - Operating profit EBITDA|Net earnings per share for the trailing year Generation Bio|GBIO - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months generationbio.com|GBIO - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Generation Bio Co.
Fundamental valuation:GBIO - Generation Bio Corp
Manufactured products of Generation Bio

This metric calculates the percentage deviation of current net earnings per share from the same period last year. This calculation enables real-time tracking of business capitalization rates, bypassing the delays of official financial reporting. Analyzing the YoY earnings per share trend reveals hidden efficiency patterns. For Generation Bio Co. (GBIO), this reflects the monetization of the eDNA platform through partnerships with pharma behemoths. The indicator's growth confirms the commercial validation of gene technologies.

Main competitors

TEM: Net earnings per one share growth for the current year|QGEN (Qiagen Group) - Earnings growth in current year|Isis Pharmaceuticals (IONS) - Expected net earnings per share growth this year|Earnings per share growth in current year Repligen Corporation (RGEN)|RNA - Earnings per share growth rate in current year|Earnings per share growth in current year CRISPR Therapeutics CRSP|WGS: Earnings per share growth this year|RARE: Net earnings per share growth this year|Earnings per share increase in current year BEAM (Beam Tx)|SRPT: Earnings growth in current year|TWST (twistbioscience.com) - Earnings per share growth in current year|TXG (10x Genomics) - Earnings growth in current year|Intellia Therapeutics Inc (NTLA) - Expected net earnings per share growth this year|Earnings per share growth in current year Stoke (STOK)|BLFS - Earnings per share growth rate in current year|Wave Life Sciences - Net earnings per share growth this year|Earnings per share increase in current year MAZE|Sionna Therapeutics - Earnings growth in current year|Prime Medicine Inc (PRME) - Net earnings per share growth this year|Taysha (TSHA) - Earnings per share growth in current year|Earnings per share growth rate in current year uniQure Pharma (QURE)|Net earnings per share growth this year MGTX|regenxbio.com (RGNX) - Expected net earnings per share growth this year|Earnings growth in current year SLDB|Ocugen Inc (OCGN) - Net earnings per share change in current year|Earnings growth in current year PACB (Pacific Biosciences of California)|Benitec Corp - Earnings per share growth in current year|Design Therapeutics - Earnings growth in current year|Expected net earnings per share growth this year rocketpharma.com RCKT|4D Molecular Therapeutics, Inc. (FDMT) - Earnings per share growth in current year|Earnings per share growth rate in current year Lexeo Therapeutics, Inc. (LXEO)|KRRO (Korro Bio Inc.) - Earnings growth in current year|Earnings per share growth this year EDIT (Editas Corp)|Earnings per share growth in current year Silence Therapeutics (SLN)|proqr.com - Earnings per share growth this year|Earnings growth in current year CDXS (Codexis)|Earnings growth in current year Sangamo Therapeutics Inc. SGMO|Nautilus Biotechnology Inc - Earnings growth in current year|Net earnings per share change in current year Metagenomi Therapeutics (MGX)|DTIL: Earnings growth in current year|Earnings per share growth rate in current year boundlessbio.com (BOLD)|Earnings per share growth in current year Exicure Inc.|Earnings per share growth this year IMNN (Celsion Corporation)|Earnings growth in current year PHIO|MBIO - Earnings per share growth rate in current year|Earnings per share growth in current year TransCode Therapeutics, Inc. RNAZ|Earnings per share increase in current year BNGO|Applied DNA Sciences, Inc. - Earnings growth in current year|BLUE - Earnings growth in current year|IPA (immunoprecise.com) - Net earnings per share growth this year|OMGA: Net earnings per one share growth for the current year|OMIC (Singular Genomics Systems) - Earnings growth in current year|regulusrx.com (RGLS) - Expected net earnings per share growth this year|Earnings per share growth in current year Syros Pharmaceuticals, Inc. (SYRS)|TBIO - Earnings per share growth rate in current year|Earnings per share growth in current year TRACON TCON|UBX: Earnings per share growth this year